Skip to main content

Cardiotoxicity of novel anti-cancer therapies

The cardiotoxicity of cancer treatments is a significant research space in the cardio-oncology field. 

For this Cardio-Oncology article collection, we welcome submissions examining cardiotoxicity caused by chemotherapy, radiotherapy, molecular-targeted agents, and immune-modulating agents. Manuscripts investigating cardiotoxicity related to novel cancer treatments will be highly appreciated.

Articles published in the collection have already gone through the systematic peer review process of the journal.

This collection is no longer accepting submissions.

New Content Item

 

Page 1 of 2

  1. Cardio-inflammatory immune related adverse events (irAEs) while receiving immune checkpoint inhibitor (ICI) therapy are particularly consequential due to their associations with poorer treatment outcomes. Eval...

    Authors: Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Pranav M. Patel, Yoshito Zamami and Aya F. Ozaki
    Citation: Cardio-Oncology 2025 11:40
    Content type: Research Published on:

  2. Evidence suggests immune checkpoint inhibitor (ICI) can increase the risk of myocarditis. We investigated it in a large national cohort in China.

    Authors: Fu-Xiao Li, Jia-Xin Cai, Ji-Bin Li, Kong-Jia Luo, Shi-Yu Wang, Wei-Hua Meng, Feng Sha, Zhi-Rong Yang, Allan Hackshaw and Jin-Ling Tang
    Citation: Cardio-Oncology 2025 11:33
    Content type: Research Published on:

  3. Immune checkpoint inhibitor(ICI) induced cardiac immune related adverse events are challenging to study; Leveraging large data bases like TriNetX global health network may provide needed insights.

    Authors: Aya F. Ozaki, Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Ali Naqvi, Nareh Nowrouzi, Yoshito Zamami and Pranav M. Patel
    Citation: Cardio-Oncology 2025 11:26
    Content type: Correspondence Published on:

  4. Fluoropyrimidines, including 5-fluorouracil and capecitabine, are the most common chemotherapeutic agents for colorectal carcinoma. Although previous studies have suggested varying degrees of cardiotoxicity wi...

    Authors: Chun-Ka Wong, Isaac Ho, Ali Choo, Rachel Lau, Ting-Fung Ma, Alston Conrad Ho-On Chiu, Tsun-Ho Lam, Minqing Lin, Ricky Wang-Hei Leung, Frankie Chor-Cheung Tam, Dominic Chi Chung Foo and Hung-Fat Tse
    Citation: Cardio-Oncology 2025 11:3
    Content type: Research Published on:

  5. Although anthracycline-related cardiotoxicity is widely studied, only a limited number of echocardiographic studies have assessed cardiac function in breast cancer survivors (BCSs) beyond ten years from anthra...

    Authors: Mali Sæter, Sara Hassing Johansen, Kristin Valborg Reinertsen, Lene Thorsen, Kristina Hermann Haugaa, Tormod Skogstad Nilsen and Sebastian Imre Sarvari
    Citation: Cardio-Oncology 2025 11:1
    Content type: Research Published on:

  6. Venous thromboembolic events (VTE) are often diagnosed in ALK-positive lung cancer although it has not been demonstrated how their co-occurrence affects patients' survival.

    Authors: Magdalena Zaborowska-Szmit, Sebastian Szmit, Marta Olszyna-Serementa, Katarzyna Zajda, Anna Janowicz-Żebrowska, Piotr Jaśkiewicz, Dariusz M. Kowalski and Maciej Krzakowski
    Citation: Cardio-Oncology 2024 10:79
    Content type: Research Published on:

  7. Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury. Our objectives were to r...

    Authors: Takeshi Onoue, Andrew H. Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M. Smith, Shannon R. McCurdy, Michael G. Fradley, Joseph Carver, Jesse Chittams and Marielle Scherrer-Crosbie
    Citation: Cardio-Oncology 2024 10:75
    Content type: Correspondence Published on:

  8. There have been several reports showing that heart-related deaths are common in long-term survivors of esophageal cancer after radiation therapy; however, radiotherapy technology is evolving year by year. This...

    Authors: Yuta Sato, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Hinako Harada, Yasuhiro Seki, Nanae Chiba, Shinsaku Okuda and Keiichi Jingu
    Citation: Cardio-Oncology 2024 10:73
    Content type: Research Published on:

  9. Trabectedin (Tbt) is an alkylating agent prescribed for soft tissue sarcomas after treatment failure of first line agents. While cardiomyopathy can occur with Tbt treatment after anthracycline exposure, Tbt-in...

    Authors: Annie J. Tsay, Mohan Satish, Elizabeth Corley, Ashley Ezema, Neisha DeJesus, Stephen Wisely, Eileen McAleer, Chen Zhang, Su Yuan, Edwin Homan, Jennifer E. Liu, Jonathan W. Weinsaft, Sandra D’Angelo, Stephanie A. Feldman and Angel T. Chan
    Citation: Cardio-Oncology 2024 10:70
    Content type: Case Report Published on:

  10. While trastuzumab has been shown to improve disease-free and overall survival in patients with HER2-positive breast cancer, it may also cause trastuzumab-induced cardiotoxicity (TIC). Although racial and ethni...

    Authors: Anna Vaynrub, Leila Mishalani, Jayant Raikhelkar and Katherine D. Crew
    Citation: Cardio-Oncology 2024 10:68
    Content type: Research Published on:

  11. Clinical outcomes for TAVR in cancer survivors with prior chest radiation therapy (C-XRT) who develop symptomatic aortic-valve stenosis are not adequately assessed in major clinical trials leading to conflicti...

    Authors: Farah Yasmin, Abdul Moeed, Muhammad Tanveer Alam, Vikash Virwani, Yumna Khabir, Asim Shaikh, Apurva V. Vyas and M. Chadi Alraies
    Citation: Cardio-Oncology 2024 10:61
    Content type: Review Published on:

  12. Immune Checkpoint Inhibitors (ICIs) have revolutionized cancer therapy. This study examines the cardiovascular risks of ICIs compared to non-ICI therapies.

    Authors: Jian-Rong Peng, Jason Chia-Hsun Hsieh, Chih-Hao Chang, Chi Chuang, Yu-Ching Wang, Tzu-Yang Chen, Hung-Chi Su and Hsin-Fu Lee
    Citation: Cardio-Oncology 2024 10:59
    Content type: Research Published on:

  13. Cardiovascular toxicity represents a significant adverse consequence of cancer therapies, yet there remains a paucity of effective biomarkers for its timely monitoring and diagnosis. To give a first evidence a...

    Authors: Xiaohe Hao, Zhenyu Zhang, Jing Kong, Rufei Ma, Cuiping Mao, Xun Peng, Kun Ru, Lisheng Liu, Chuanxi Zhao, Xinkai Mo, Meijuan Cai, Xiangguo Yu and Qinghai Lin
    Citation: Cardio-Oncology 2024 10:56
    Content type: Research Published on:

  14. Within cardio-oncology, emerging epidemiologic studies have demonstrated a bi-directional relationship between heart failure (HF) and cancer. In the current study, we aimed to further explore this relationship...

    Authors: P. F. van den Berg, L. I. Yousif, G. Markousis-Mavrogenis, C. Shi, V. Bracun, J. Tromp, S. de Wit, Y. Appels, E. M. Screever, J. P. Aboumsallem, W. Ouwerkerk, D. J. van Veldhuisen, H. H. W. Silljé, A. A. Voors, R. A. de Boer and Wouter C. Meijers
    Citation: Cardio-Oncology 2024 10:47
    Content type: Research Published on:

  15. The therapeutic landscape of chronic myeloid leukaemia (CML) has been transformed by tyrosine kinase inhibitors (TKI). Nilotinib, showed higher rates of major molecular response than imatinib, however associat...

    Authors: Fiona Fernando, Maria Sol Andres, Simone Claudiani, Nazanin Zounemat Kermani, Giulia Ceccarelli, Andrew J. Innes, Afzal Khan, Stuart D. Rosen, Jane F. Apperley, Alexander R. Lyon and Dragana Milojkovic
    Citation: Cardio-Oncology 2024 10:42
    Content type: Research Published on:

  16. Immune checkpoint inhibitors (ICIs)-associated myocarditis was a rare yet severe complication observed in individuals undergoing immunotherapy. This study investigated the immune status and characteristics of ...

    Authors: Peng Yan, Yanan Liu, Mingyan Zhang, Ning Liu, Yawen Zheng, Haiqin Zhang, Hao Zhou and Meili Sun
    Citation: Cardio-Oncology 2024 10:35
    Content type: Research Published on:

  17. First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated...

    Authors: Srilakshmi Vallabhaneni, Srinath Adusumalli, Jingyi Wu, Peter W. Groeneveld, James Gerson and Rupal P. O’Quinn
    Citation: Cardio-Oncology 2024 10:33
    Content type: Research Published on:

  18. Despite the growing use of immune checkpoint inhibitors (ICI) in cancer treatment, data regarding ICI-associated pericardial disease are primarily derived from case reports and case series. ICI related pericar...

    Authors: Sarah E. Mudra, Danny L. Rayes, Ankit Agrawal, Ashwin K. Kumar, Jason Z. Li, Meredith Njus, Kevin McGowan, Kazi A. Kalam, Charalompos Charalampous, Mary Schleicher, Muhammad Majid, Alvena Syed, Abdullah Yesilyaprak and Allan L. Klein
    Citation: Cardio-Oncology 2024 10:29
    Content type: Research Published on:

  19. Breast cancer is estimated to comprise about 290,560 new cases in 2022. Aromatase inhibitors (AIs) are recommended as adjuvant treatment for estrogen-receptor positive (ER+) breast carcinoma in postmenopausal ...

    Authors: Adnan Shaaban, Ashley Petersen, Heather Beckwith, Natalia Florea, David A. Potter, Douglas Yee, Rachel I. Vogel, Daniel Duprez and Anne H. Blaes
    Citation: Cardio-Oncology 2024 10:27
    Content type: Research Published on:

  20. Anthracyclines can cause left ventricular (LV) dysfunction. There is little data about right ventricular (RV) damage during chemotherapy.

    Authors: Ludovico Rossetto, Daniela Di Lisi, Cristina Madaudo, Francesco Paolo Sinagra, Antonio Di Palermo, Oreste Fabio Triolo, Grazia Gambino, Antonella Ortello, Alfredo Ruggero Galassi and Giuseppina Novo
    Citation: Cardio-Oncology 2024 10:24
    Content type: Research Published on:

  21. Panitumumab is a human immunoglobulin monoclonal antibody designed to target the epidermal growth factor receptor (EGFR) which is used in the treatment of metastatic colorectal cancer alone or in combination w...

    Authors: Isabelle Senechal, Nikolaos Vogiatzakis, Maria Sol Andres, Jieli Tong, Sivatharshini Ramalingam, Stuart D Rosen, Alexander R Lyon and Muhummad Sohaib Nazir
    Citation: Cardio-Oncology 2024 10:23
    Content type: Case Report Published on:

  22. Chimeric Antigen Receptor-T (CAR-T) cell infusion is a rapidly evolving antitumor therapy; however, cardiovascular (CV) complications, likely associated with cytokine release syndrome (CRS) and systemic inflam...

    Authors: Massimiliano Camilli, Marcello Viscovo, Tamara Felici, Luca Maggio, Federico Ballacci, Giacomo Carella, Alice Bonanni, Priscilla Lamendola, Lorenzo Tinti, Antonio Di Renzo, Giulia Coarelli, Eugenio Galli, Giovanna Liuzzo, Francesco Burzotta, Rocco Antonio Montone, Federica Sorà…
    Citation: Cardio-Oncology 2024 10:18
    Content type: Research Published on:

  23. Capecitabine, a pro-drug of 5-fluorouracil, is commonly used in the treatment of breast and colorectal cancer. Its side effects, including nausea, vomiting, diarrhea, fatigue, loss of appetite, and bone marrow...

    Authors: Maciej Kabat, Roma Padalkar, Sara Hazaveh, Vladimir Joseph, David Feigenblum and Sean Sadikot
    Citation: Cardio-Oncology 2024 10:11
    Content type: Case Report Published on:

  24. Cardiotoxicity is one of the most common adverse events of the chemotherapy. Physical exercise was shown to be cardioprotective. We aim to estimate the efficacy and safety of exercise in cancer patients receiv...

    Authors: Ahmed Mazen Amin, Yehya Khlidj, Mohamed Abuelazm, Ahmed A. Ibrahim, Mohammad Tanashat, Muhammad Imran, Abubakar Nazir, Hosam Shaikhkhalil and Basel Abdelazeem
    Citation: Cardio-Oncology 2024 10:10
    Content type: Review Published on:

  25. This article provides an up-to-date overview of pericardial effusion in oncological practice and a guidance on its management. Furthermore, it addresses the question of when malignancy should be suspected in c...

    Authors: S. Mori, M. Bertamino, L. Guerisoli, S. Stratoti, C. Canale, P Spallarossa, I. Porto and P. Ameri
    Citation: Cardio-Oncology 2024 10:8
    Content type: Review Published on:

  26. Early identification of patients susceptible to chemotherapy-induced cardiotoxicity could lead to targeted treatment to reduce cardiac dysfunction. Rats treated with doxorubicin (DOX), a chemotherapeutic agent...

    Authors: Julia Matzenbacher dos Santos, Aby Joiakim, David A. Putt, Marielle Scherrer-Crosbie and Hyesook Kim
    Citation: Cardio-Oncology 2023 9:47
    Content type: Research Published on:

  27. Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiov...

    Authors: Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac and Ghazwa B. Korayem
    Citation: Cardio-Oncology 2023 9:35
    Content type: Research Published on:

  28. Immune checkpoint inhibitor (ICI) myocarditis is associated with significant mortality risk. Electrocardiogram (ECG) changes in ICI myocarditis have strong prognostic value. However the impact of complete hear...

    Authors: Michael P. O’Shea, Suganya Arunachalam Karikalan, Ali Yusuf, Timothy Barry, Eiad Habib, John O’Shea, Michael Killian, Eman Baqal, Srishti Nayak, Rajeev Masson, Joerg Hermann, Shimoli Shah, Chadi Ayoub and Hicham El Masry
    Citation: Cardio-Oncology 2023 9:34
    Content type: Research Published on:

  30. Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction.

    Authors: Matthew Dean, Min Jung Kim, Sharon Dimauro, Susan Tannenbaum, Garth Graham, Bruce T. Liang and Agnes S. Kim
    Citation: Cardio-Oncology 2023 9:23
    Content type: Research Published on:

  32. Many ca. survivors exhibit signs of IR, an important risk factor for the development of CAD. CAC scans offer a risk assessment of CV disease before cardiac damage has occurred. We investigated how IR affects C...

    Authors: N. Jacobi, S. Ortman, L. Buda and Daniel Duprez
    Citation: Cardio-Oncology 2023 9:21
    Content type: Research Published on:

  33. Despite the cardiotoxic effect of anthracycline on the left ventricle (LV) was totally identified. The assessment of the anthracycline effect on the right ventricle(RV) by conventional echocardiography was a c...

    Authors: Wafaa S. El-Sherbeny, Nesreen M. Sabry, Shaimaa B. El-Saied and Basma Elnagar
    Citation: Cardio-Oncology 2023 9:20
    Content type: Research Published on:

  34. Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute co...

    Authors: Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Rahul Mhaskar, Kayla Reid, Sae Bom Lee, Salvatore Corallo, Melanie J. Hidalgo-Vargas, Abhishek Kumar, Julio Chavez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Rawan Faramand…
    Citation: Cardio-Oncology 2023 9:18
    Content type: Research Published on:

  35. Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or ...

    Authors: Ali Mir, Yasra Badi, Seif Bugazia, Anas Zakarya Nourelden, Ahmed Hashem Fathallah, Khaled Mohamed Ragab, Mohammed Alsillak, Sarah Makram Elsayed, Abdulrahman Ibrahim Hagrass, Sawyer Bawek, Mohamad Kalot and Zachary L. Brumberger
    Citation: Cardio-Oncology 2023 9:10
    Content type: Review Published on:

  36. Prostate cancer has a very high prevalence among elder men, and this could potentially increase as longevity in many parts of the world is increasing. Early stages of prostate cancer can have surgical options,...

    Authors: Aswini Kumar, Aswanth Reddy and Arjun Sekar
    Citation: Cardio-Oncology 2023 9:9
    Content type: Case Report Published on:

  37. Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer ...

    Authors: Charlie Wang, Sophia Zoungas, Mabel Yan, Rory Wolfe, Andrew Haydon, Mark Shackleton, Mark Voskoboynik, Maggie Moore, Miles C. Andrews, Stephen J. Nicholls and Victoria Mar
    Citation: Cardio-Oncology 2022 8:23
    Content type: Research Published on:

  38. The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events (cvAEs) by pres...

    Authors: Maria Sol Andres, Sivatharshini Ramalingam, Stuart D. Rosen, John Baksi, Rajdeep Khattar, Yulia Kirichenko, Kate Young, Nadia Yousaf, Alicia Okines, Robert Huddart, Kevin Harrington, Andrew J.S. Furness, Samra Turajlic, Lisa Pickering, Sanjay Popat, James Larkin…
    Citation: Cardio-Oncology 2022 8:21
    Content type: Research Published on:

  39. We report the case of a 59-year-old female patient with no previous cardiovascular disease treated for Breast cancer with Capecitabine. Shortly after starting treatment, she developed recurrent angina. An exer...

    Authors: George B. Strobel, Shiva P. Ponamgi, Attila Roka and Ahmed S. A. Aboeata
    Citation: Cardio-Oncology 2022 8:19
    Content type: Case Report Published on:

  40. Acute pericarditis is caused by the inflammation of the pericardium which can result in an effusion around the heart. Proton beam therapy causing radiation-induced pericarditis is not a well-known cause of per...

    Authors: Rahul Gupta, Muling Lin, Gary M. Freedman, Deborah W. Sundlof and Cheri Silverstein Fadlon
    Citation: Cardio-Oncology 2022 8:9
    Content type: Correspondence Published on:

  41. Androgen deprivation therapy (ADT) and radiotherapy (RT) are the mainstay treatment for localized prostate cancer and recurrence after surgery. Cardiovascular (CV) toxicity of ADT is increasingly recognized, a...

    Authors: Youquan Li, Whee Sze Ong, Ma Than Than Shwe, Nelson Ling Fung Yit, Sheriff Zhan Hong Quek, Eric Pei Ping Pang, Wen Shen Looi, Wen Long Nei, Michael Lian Chek Wang, Melvin Lee Kiang Chua, Terence Wee Kiat Tan, Eu Tiong Chua, Choon Ta Ng and Jeffrey Kit Loong Tuan
    Citation: Cardio-Oncology 2022 8:4
    Content type: Research Published on:

  42. Checkpoint-inhibitor immunotherapies have had a profound effect in the treatment of cancer by inhibiting down-regulation of T-cell response to malignancy. The cardiotoxic potential of these agents was first de...

    Authors: Zachary L. Brumberger, Mary E. Branch, Max W Klein, Austin Seals, Michael D. Shapiro and Sujethra Vasu
    Citation: Cardio-Oncology 2022 8:3
    Content type: Research Published on:

  43. Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flu...

    Authors: Juan Carlo Avalon, Jacob Fuqua, Tyler Miller, Seth Deskins, Chelby Wakefield, Austin King, Sonya Inderbitzin-Brooks, Christopher Bianco, Lauren Veltri, Wei Fang, Michael Craig, Abraham Kanate, Kelly Ross, Midhun Malla and Brijesh Patel
    Citation: Cardio-Oncology 2021 7:38
    Content type: Research Published on:

  44. Gilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia. However, gilteritinib...

    Authors: Lisa Kim, Brian Fowler, Courtney M. Campbell, Jeremy Slivnick, Haseeb Nawaz, Yaquta Kaka, Patrick Ruz, Ajay Vallakati, Ragavendra Baliga, Sumithira Vasu and Daniel Addison
    Citation: Cardio-Oncology 2021 7:36
    Content type: Case report Published on:

  45. Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt ...

    Authors: A Mecinaj, G Gulati, SL Heck, E Holte, MW Fagerland, AI Larsen, E.S Blix, J Geisler, T Wethal and T Omland
    Citation: Cardio-Oncology 2021 7:33
    Content type: Research Published on:

  46. Modern therapies in oncology have increased cancer survivorship, as well as the incidence of cardiovascular adverse events. While immune checkpoint inhibitors have shown significant clinical impact in several ...

    Authors: Jessica Castrillon Lal, Sherry-Ann Brown, Patrick Collier and Feixiong Cheng
    Citation: Cardio-Oncology 2021 7:19
    Content type: Research Published on:

  47. The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact...

    Authors: Jennifer K. Lang, Badri Karthikeyan, Adolfo Quiñones-Lombraña, Rachael Hageman Blair, Amy P. Early, Ellis G. Levine, Umesh C. Sharma, Javier G. Blanco and Tracey O’Connor
    Citation: Cardio-Oncology 2021 7:17
    Content type: Research Published on:

  48. Breast cancer is the most common female cancer worldwide. Effective therapies including doxorubicin and trastuzumab have improved survival, but are associated with a substantial risk of cardiovascular disease....

    Authors: Rebecca K. Hoffman, Bang-Jin Kim, Payal D. Shah, Joseph Carver, Bonnie Ky and Sandra Ryeom
    Citation: Cardio-Oncology 2021 7:15
    Content type: Research Published on:

  49. Trastuzumab reduces risk of breast cancer recurrence but carries risk of cardiotoxicity that may be reversible upon treatment cessation and institution of left ventricular (LV) enhancement therapies (LVETx). W...

    Authors: Ren Jie Robert Yao, Jordan Gibson, Christine Simmons and Margot K. Davis
    Citation: Cardio-Oncology 2021 7:12
    Content type: Research Published on:

  50. Immune checkpoint inhibitors (ICIs) are a novel class of anticancer agents that have demonstrated clinical response for both solid and hematological malignancies. ICIs are associated with development of immune...

    Authors: Nida Waheed, Michael G. Fradley, David L. DeRemer, Ahmad Mahmoud, Chintan P. Shah, Taimour Y. Langaee, Gloria P. Lipori, Keith March, Carl J. Pepine, Rhonda M. Cooper-DeHoff, Yonghui Wu and Yan Gong
    Citation: Cardio-Oncology 2021 7:10
    Content type: Research Published on: